Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus

NCT04615013 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04615013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04615013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
November 23, 2020
Completion date
October 31, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical esophagus adenocarcinoma, clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage iia esophageal adenocarcinoma ajcc v8, clinical stage iib esophageal adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, gastroesophageal junction adenocarcinoma, pathologic stage ii esophageal adenocarcinoma ajcc v8, pathologic stage iia esophageal adenocarcinoma ajcc v8, pathologic stage iib esophageal adenocarcinoma ajcc v8, pathologic stage iii esophageal adenocarcinoma ajcc v8, pathologic stage iiia esophageal adenocarcinoma ajcc v8, pathologic stage iiib esophageal adenocarcinoma ajcc v8, thoracic esophagus adenocarcinoma